Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 11, Issue 1, Pages 10-11Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2013.231
Keywords
-
Categories
Ask authors/readers for more resources
The international phase III REGARD study demonstrated improved overall survival with ramucirumab as second-line therapy for patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma. As a novel biological treatment, is ramucirumab also the harbinger of a new era of targeted therapies in this prevalent and highly morbid disease?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
